We compared the effect of 4 anti-muscarinic agents on bladder activity, urinary ATP levels, and autonomic nervous system in rats. Rats were divided into the following 5 groups (control group, oxybutynin group, propiverine group, tolterodine group, imidafenacin group), and were administered daily the designated anti-muscarinic agent or distilled water into the stomach. After 2 weeks, we performed 1) continuous cystometry with physiological saline and 0.1% acetic acid solution, 2) measurement of urinary ATP level before and after bladder stimulation, and 3) measurement of the heart rate, blood pressure and plasma catecholamines. The maximum bladder contraction pressure increased and the interval between contractions became shorter during cystometry with acetic acid solution in the control group, but not in the 4 anti-muscarinic agent groups. The urinary ATP level increased after bladder stimulation in all groups, but the increase was smaller in the propiverine and imidafenacin groups. The plasma noradrenaline and dopamine levels of the propiverine group were higher. Taken together, all anti-muscarinic agents inhibited the bladder activity without changing the heart rate and blood pressure. Especially, the inhibitory effect of propiverine and imidafenacin on bladder activity may be partly due to blocking an increase of ATP release from the bladder urothelium.
Bladder smooth muscle cells contract when exposed to acetylcholine released from the parasympathetic nerve terminals, and anti-muscarinic agents are thought to inhibit bladder contraction by blocking the muscarinic receptors expressed on bladder smooth muscle (9, 10) . Recently, it has been reported that the bladder urothelium secretes non-neurogenic acetylcholine, and that muscarinic receptors are expressed on bladder epithelial cells and on afferent nerve terminals in the bladder (3) . The bladder urothelium also produces adenosine triphosphate (ATP) and the afferent nerve terminals in the bladder have purinergic receptors (14) . In an animal experiment, ATP secreted by bladder epithelial cells influenced bladder activity, while a muscarinic receptor agonist evoked the release of ATP from cultured bladder epithelial cells (5) . Therefore, antimuscarinic agents may inhibit involuntary bladder contraction by blocking both non-neurogenic acetylcholine and ATP secretion by the bladder urothelium, and this may be the main mechanism underlying the inhibition of bladder contraction by anti-muscarinic agents. Anti-muscarinic agents are the treatment of choice for urinary frequency, and their efficacy, tolerability, and safety have been well established by various studies and in clinical practice. Recently, several anti-muscarinic agents with better tolerated and various special features have been developed. Antimuscarinic agents are also known to act on the autonomic nervous system because they suppress the parasympathetic nervous system by inhibiting the binding of the acetylcholine to the muscarinic intravesical baseline pressure, and the maximum bladder contraction pressure were measured during the final 30 min.
Study 2 Measurement of urinary ATP.
Another 35 rats (7 from each group) were taken out of the cages and placed on a clean board, and the spontaneously voided urine was carefully collected from each rat. After that, the rats were anesthetized with 2% isoflurane, and 1 mL of 0.1% acetic acid solution was infused into the bladder via a catheter for 10 min as bladder stimulation. The animals also received a subcutaneous injection of 100 mg of cefazolin sodium hydrate (Astellas, Tokyo, Japan) to prevent urinary tract infection. Spontaneously voided urine was collected at 4-6 h (day 0) after recovery from anesthesia, as well as on day 1, day 2, day 3, and day 7 after bladder stimulation. During this period after infusion of the acetic acid solution into the bladder, administration of distilled water or the anti-muscarinic agents was continued. The urinary ATP level was measured with an ATP Hygiene Kit HS (Bio Thema AB, Haninge, Sweden) and Gene Light 55 (Microtec Nition, Funabashi, Japan), and the results were corrected by the urinary creatinine (CRE) level.
Study 3 Measurement of heart rate, blood pressure, and plasma catecholamines. We performed measurement of heart rate, blood pressure, and plasma catecholamines in the remaining 25 rats (5 from each group). The heart rate and blood pressure (systolic, mean, and diastolic) were measured in conscious and restrained rats by the tail-cuff method using a programmed sphygmomanometer (BP-98A; Softron, Tokyo, Japan). Each animal was restrained for 15 min in a temperature-controlled warming holder (37°C) designed for rats before measurement. The average of three recordings taken at 1 min intervals was calculated. After the heart rate and blood pressure measurements, each rat was anesthetized with 2% isoflurane, and blood was withdrawn from the vena cava. The blood sample was centrifuged at 3,000 rpm for 10 min, after which plasma catecholamines (noradrenaline, adrenaline, and dopamine) were measured by high performance liquid chromatography.
Statistical analysis.
Results are reported as the mean ± standard deviation (SD). Student's paired or unpaired t-test was used for statistical analysis, and P < 0.05 was considered to indicate statistical significance.
receptor. In the present study, we compared the effects of 4 anti-muscarinic agents on bladder activity in rats before and after bladder stimulation, as well as on urinary ATP levels, heart rate, blood pressure, and plasma catecholamines.
MATERIALS AND METHODS

Materials.
Ninety-five female Sprague-Dawley rats weighing 218-231 g were used in this study. The protocol for this study was approved by the Institutional Animal Care and Use Committee of the University of the Ryukyus. The rats were divided into five groups, which were a control group (n = 19), an oxybutynin group (n = 19), a propiverine group (n = 19), a tolterodine group (n = 19), and an imidafenacin group (n = 19). Rats from the propiverine group and tolterodine group were administered 5 mg of propiverine hydrochloride (1) or 0.5 mg of tolterodine tartrate (1) dissolved in distilled water (0.5 mL) in the morning into the stomach via a fine catheter without anesthesia. In the evening, these rats were also administered the same volume of distilled water alone. Rats from the oxybutynin group and imidafenacin group were administered 0.5 mg of oxybutynin hydrochloride (1) or 12 μg of imidafenacin (12) dissolved in distilled water twice a day. These drugs were offered from the Taiho Pharmaceutical Co., Ltd, Tokushima, Japan. The doses of these 4 drugs were about 20 times the human dosage. Rats from the control group were administered the same volume of distilled water twice a day. Each group was treated for 2 weeks, and rats were given free access to diet and tap water during that period. Then the following studies were performed.
Study 1 Continuous cystometry.
Thirty-five rats (7 from each group) were anesthetized with urethane (0.8 g/kg subcutaneously and 0.4 g/kg intraperitonealy), and a small-bore catheter (PE50; Clay Adamus, USA) was inserted into the bladder through the urethra to perform continuous cystometry. Physiological saline was infused into the bladder (0.05 mL/min) via the catheter and bladder activity was monitored. Cystometry was continued for at least 60 min, and the interval between bladder contractions, the intravesical baseline pressure, and the maximum bladder contraction pressure were measured during the final 30 min. After cystometry had been performed with physiological saline, the rats also underwent continuous cystometry with a 0.1% acetic acid solution. Cystometry was again continued for at least 60 min, and the interval between bladder contractions, the of the control value, P = 0.023) than in control group. On day 1, the urinary ATP/CRE ratio was also significantly lower in the propiverine group (15% of the control value, P < 0.001) and the imidafenacin group (15% of the control value, P = 0.023) compared with that of the control group. Although the urinary ATP/CRE ratio was also lower on day 0 in the oxybutynin group (43% of the control value), the difference was not significant. Administration of tolterodine did not influence the
RESULTS
Study 1
During continuous cystometry with physiological saline, there were no significant differences of any of the cystometric parameters among the 5 groups. When continuous cystometry was performed with 0.1% acetic acid, the maximum bladder contraction pressure was significantly higher (14% increase, P = 0.001) and the interval between bladder contractions was significantly shorter (22% decrease, P = 0.003) in the control group compared with the results obtained during cystometry using physiological saline (Table 1) . However, there were no significant differences of cystometric parameters between physiological saline and 0.1% acetic acid in the 4 anti-muscarinic agent groups.
Study 2
Before infusion of 0.1% acetic acid into the bladder, the urinary ATP level corrected by urinary creatinine (the urinary ATP/CRE ratio) did not differ among the 5 groups (1-6 mol/mg Cre × E-10). After bladder stimulation, the urinary ATP/CRE ratio was increased significantly on day 0 in all 5 groups compared with before infusion of the acetic acid solution, and the ratio gradually decreased over time (Fig. 1) . Comparison of the urinary ATP/CRE ratios on day 0 showed that the ratio was significantly lower in the propiverine group (16% of the control value, P < 0.001) and the imidafenacin group (43% Values are mean ± SD, **:P < 0.01 ** ** Fig. 1 Change of the urinary ATP/CRE ratio with bladder stimulation by 0.1% acetic acid solution. The urinary ATP/ CRE ratio significantly increased in all 5 groups after the bladder stimulation, but its degree was significantly smaller in the propiverine group and imidafenacin group than the control group on day 0 and day 1.
contraction pressure and the reduction of the interval between bladder contractions caused by acetic acid infusion into the bladder. The pharmacokinetics and adverse effects of these drugs differ somewhat due to differences of structure, muscarinic receptor subtype selectivity, and organ selectivity (1). Therefore, we also compared the effect of the 4 anti-muscarinic agents on the urinary ATP level and the autonomic nervous system, in addition to bladder activity. Acetylcholine is the primary contractile neurotransmitter in the bladder, and anti-muscarinic agents act by inhibiting the binding of acetylcholine to muscarinic M 2 and M 3 receptors on bladder smooth muscle cells and other structures within the bladder wall. Recent studies have suggested that ATP produced by bladder epithelial cells has an influence on bladder activity (3, 5, 10, 14) and muscarinic agonists have been shown to evoke the release of ATP from cultured bladder epithelial cells (5) . In the present study, propiverine and imidafenacin inhibited the increase of urinary ATP after bladder stimulation. Therefore, the inhibitory effect of antimuscarinic agents on bladder contraction might depend on blocking ATP secretion by the bladder urothelium as well as preventing the binding of acetylcholine to muscarinic receptors on bladder smooth muscle cells. The bladder urothelium is thought to play an urinary ATP/CRE ratio after bladder stimulation. The urinary ATP/CRE ratio of each group returned to baseline by day 3 and day 7, and there were no significant differences among the 5 groups at that time (Fig. 1) .
Study 3
The plasma noradrenaline and dopamine levels of the propiverine group were significantly higher (noradrenaline: 123% increase of the control value, P < 0.001; dopamine: 176% increase of the control value, P = 0.026) than those of the control group (Table 2) . However, no significant differences of heart rate or blood pressure were observed between the propiverine group and the control group (Table 3). There was also no significant difference of heart rate, blood pressure plasma, and catecholamine levels among the other 3 anti-muscarinic agent groups and the control group (Tables 2 and 3 ).
DISCUSSION
Several anti-muscarinic agents are used as standard treatment for overactive bladder (OAB), and the efficacy of these drugs for the symptoms of OAB patients has been demonstrated. In the present study, we examined the effect of 4 different anti-muscarinic agents on bladder activity, and found that all 4 agents inhibited the increase of maximum bladder Values are mean ± SD. *: P < 0.05, ***: P < 0.001 *** * (15) . Activation of the M 1 , M 2 , and M 3 mAChR subtypes results in ATP release, and this is blocked by an mAChR antagonist (15) . However, some of studies have shown that the distribution of mAChR subtypes varies between different layers of the urothelium (7). In mice and humans, the M 1 mAChR is mainly expressed on the basal plasma membrane of the basal cells and the M 2 mAChR is restricted to the umbrella cells, but the M 3 , M 4 , and M 5 mAChRs are distributed throughout the urothelium. In the present study, imidafenacin (which has a high affinity for the M 1 and M 3 mAChRs) (12) inhibited the increase of urinary ATP after chemical bladder stimulation, while tolterodine (which has a high affinity for the M 2 mAChR) (1) did not alter the urinary ATP level, although both drugs inhibited bladder activity during continuous cystometry. Therefore, the changes of urinary ATP may not be caused by any unique effect of muscarinic receptors on the urothelium. There is a possibility that acetylcholine not only acts on muscarinic receptors expressed by the urothelium, but also on those expressed by parasympathetic nerves and bladder muscle cells. Therefore, acetylcholine secreted at various sites may act on the local muscarinic receptor subtypes, and the urinary ATP level would reflect the overall activity of the bladder. ATP release after mAChR stimulation depends on the intracellular Ca 2+ level (15) . Activation of mAChRs increases Ca 2+ in cultured rat bladder epithelial cells, and induces an increase of ATP release. In the isolated rat bladder, local application of carbachol induces Ca 2+ waves originating in the urothelium and suburothelial space (13) . In the present study, propiverine strongly inhibited the increase of urinary ATP after bladder stimulation. Propiverine hydrochloride appears to have an additional spasmolytic effect in addition to its anti-muscarinic effect (2) . In rabbit, propiverine alters intracellular Ca 2+ homeostasis in addition to its muscarinic antagonist effect (16) . Because bladder contraction in response to muscarinic receptor stimulation requires the influx of Ca 2+ via nifedipine-sensitive L-type calcium channels (17), a calcium antagonist effect combined with an anti-muscarinic effect may lead to marked reduction of the urinary ATP level by propiverine. Oxybutynin has also been suggested to have a calcium antagonist effect to some extent (18) , which may cause the decrease of urinary ATP. Regarding plasma catecholamine levels, only propiverine increased the plasma noradrenaline and dopamine levels, although heart rate and blood pressure did not change. One of the reasons for this may be the antihypertensive effect of Ca 2+ antagonism. In conclusion, all anti-muscarinic agents inhibited the bladder activity without changing the heart rate and blood pressure. However, the inhibitory mechanism of bladder activity was different in each antimuscarinic agent. Especially, the inhibitory effect of propiverine and imidafenacin on bladder activity may have been partly due to blocking the increase of ATP release by the bladder urothelium, and an increase of the urinary ATP level can be used as a marker for activation of the bladder urothelium.
